Drug
Solanezumab clinical trials
Also written LY2062430.
- studies test it
- 12
- open now
- 0
- in phase 3
- 8
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 5
- Phase 3
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Eli Lilly and Company (10) · Washington University School of Medicine (2)
Often tested with
Tested in the same studies.
Gantenerumab (2) · Etalanetug (1) · Lecanemab (1) · LY-2599666 (1)
Studies
Open first, then newest update. How each study uses solanezumab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossCompletedPhase 3Eli Lilly and CompanyNCT02008357Written as Solanezumab
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Active, not recruitingPhase 2/3Washington University School of MedicineNCT01760005Written as Solanezumab
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.CompletedPhase 2/3Washington University School of MedicineNCT04623242Written as Solanezumab
- A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)TerminatedPhase 1Eli Lilly and CompanyNCT02614131Written as Solanezumab
- A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's DiseaseTerminatedPhase 3Eli Lilly and CompanyNCT02760602Written as Solanezumab
- Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus PlaceboTerminatedPhase 3Eli Lilly and CompanyNCT01900665Written as Solanezumab
- Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's DiseaseTerminatedPhase 3Eli Lilly and CompanyNCT01127633Written as Solanezumab
- Effect of LY2062430 on the Progression of Alzheimer's DiseaseCompletedPhase 3Eli Lilly and CompanyNCT00904683Written as LY2062430
- Effect of LY2062430 on the Progression of Alzheimer's DiseaseCompletedPhase 3Eli Lilly and CompanyNCT00905372Written as LY2062430
- A Biomarker Study of Solanezumab in Patients With and Without Alzheimer'sCompletedPhase 2Eli Lilly and CompanyNCT01148498Written as solanezumab
- Solanezumab Safety Study in Japanese Patients With Alzheimer's DiseaseCompletedPhase 2Eli Lilly and CompanyNCT00749216Written as Solanezumab
- Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy VolunteersCompletedPhase 2Eli Lilly and CompanyNCT00329082Written as LY2062430
Codes
What other systems call solanezumab · ClinicalTrials.gg INT005663
- MeSH (NLM) C550616solanezumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5D6PWO0333SOLANEZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7555695solanezumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88585SolanezumabOne source FDA
- DrugBank DB11756One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C550616 | solanezumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5D6PWO0333 | SOLANEZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7555695 | solanezumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88585 | Solanezumab | One source FDA |
| DrugBank | DB11756 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.